Fenofibrate is Contraindicated During Breastfeeding
Fenofibrate should not be used while breastfeeding, and women must discontinue breastfeeding during treatment and for 5 days after the final dose. This is an explicit contraindication based on FDA labeling 1.
FDA Contraindication
The FDA drug label provides clear guidance on this issue:
- No human data exists on fenofibrate presence in breast milk, effects on breastfed infants, or effects on milk production 1
- Fenofibrate is present in rat milk, making it likely to be present in human milk 1
- The primary concern is disruption of infant lipid metabolism, which could have serious consequences for the developing infant 1
- Women are explicitly instructed not to breastfeed during treatment and for 5 days after the final dose 1
Rationale for Contraindication
The concern about disrupting infant lipid metabolism is particularly significant because:
- Lipids are critical for infant brain development and growth
- Fenofibrate's mechanism of action involves altering lipid metabolism through PPARα activation
- Infants have different metabolic requirements than adults, with higher needs for cholesterol and fatty acids for neurological development
- The safety profile in infants cannot be extrapolated from adult data
Clinical Approach
If a breastfeeding woman requires lipid management:
- Discontinue breastfeeding if fenofibrate is medically necessary
- Consider alternative agents that may be safer during lactation if lipid control is needed
- Delay fenofibrate therapy until after weaning if the clinical situation allows
- Wait 5 days after the last dose before resuming breastfeeding if fenofibrate was used
Important Caveat
The animal study showing fenofibrate in rat milk 2 was actually investigating therapeutic effects in offspring, not safety concerns, but it confirms drug transfer into milk. The absence of human data combined with the theoretical risk to infant lipid metabolism justifies the conservative FDA contraindication.
Human Guidelines 3, 4 focus on cardiovascular safety and drug interactions but do not address lactation, making the FDA drug label 1 the authoritative source for this specific question.